A director at ANI Pharmaceuticals Inc sold 20,000 shares at 66.620USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows: Capital One 1st Annual Biotech/Biopharma Disruptors Event Date:Tuesday, May 14, 2024 Time:12:15pm ET To schedule a 1x1 meeting with management, please contact H.C. Wainwright 2nd Annual BioConnect Conference at N...
Our trip to South Korea and China revealed Chinese shipbuilders are seeking growth to take on Korea’s established yards who are facing constraints. An eagerness to add capacity is one of our takeaways, as well as a gloomy outlook for Chinese real estate, which in our view should inevitably weigh on dry bulk demand.
Block Advisors by H&R Block Launches ‘Fund Her Future’ Grant Program to Support Women-Owned Small Businesses Five winners will receive grants totaling $100,000 and access to Block Advisors services and experts to aid growth and create impact in their communities KANSAS CITY, Mo., April 29, 2024 (GLOBE NEWSWIRE) -- To help close the gap in funding and support for women-owned small businesses, by created the small business grant program. The program will award five women-owned small businesses a combined total of $100,000 in funding and access to a year of small business services from ...
FRO – Filing of Annual Report Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2023. The annual report can be downloaded from the Company’s website or from the link below. Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing to us at:John Kennedy 8 Iris Building, 7th floor, Flat/Office 740B, 3106, Limassol, Cyprus. or sending an e-mail to April 26, 2024 Frontline plc Limassol, Cyprus. ...
H&R Block to Release Fiscal 2024 Third Quarter Results on May 9, 2024 KANSAS CITY, Mo., April 25, 2024 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) will report fiscal 2024 third quarter results on Thursday, May 9, 2024, after the New York Stock Exchange market close. At that time, a copy of the press release and presentation will be available on the company's investor relations website at . A conference call for analysts, institutional investors, and shareholders will be held at 4:30 p.m. Eastern time on Thursday, May 9, 2024. During the conference call the company will discuss fi...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy -Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Update...
VALUE LINE, INC. ANNOUNCES 10TH CONSECUTIVE INCREASE IN ITS DIVIDEND; QUARTERLY CASH DIVIDEND OF $0.30 PER COMMON SHARE DECLARED NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Value Line, Inc. (NASDAQ: VALU) announced today that its Board of Directors declared on April 19, 2024 a quarterly cash dividend of $0.30 per common share, payable on May 10, 2024, to stockholders of record on April 29, 2024. The 2024 increase of eight cents per year when annualized represents the tenth consecutive year of increases for the 93-year-old investment research icon. Based on a full year at the new rate, t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.